Back to Search Start Over

Care Among Migraine Patients in a Commercially Insured Population

Authors :
Machaon Bonafede
Donna McMorrow
Virginia Noxon
Pooja Desai
Sandhya Sapra
Stephen Silberstein
Source :
Neurology and Therapy, Vol 9, Iss 1, Pp 93-103 (2020)
Publication Year :
2020
Publisher :
Adis, Springer Healthcare, 2020.

Abstract

Abstract Introduction Migraine management is characterized by the poor use of preventive therapy and the overuse of acute medications. An analysis of current treatment patterns in migraineurs is needed to improve care in this patient population. The aim of this study was to describe treatment patterns and healthcare utilization of newly diagnosed migraine patients. Methods This was a retrospective observation study of newly diagnosed migraine patients (no indication of migraine in the past year) identified in the IBM MarketScan Commercial Claims and Encounters database from 1 January 2010 to 30 June 2014. The final study population comprised persons aged 18–64 years at index (new diagnosis of migraine) with 12 months of continuous enrollment in an insurance plan with medical and pharmacy benefits pre-index and post-index. Treatment patterns and healthcare resource utilization were assessed during the post-index period (at least 12-months). Results Of the 1,588,666 migraine patients identified in the database as potentially eligible to participate in the study, 284,719 (17.9%) met the final inclusion criteria. Patients generally used acute and preventive therapies to manage migraine attacks, with most patients using preventive therapy (59.1%). However, 67.9% of those using preventive therapy discontinued the current therapy, with a median time to discontinuation of 5 months. Most of the patients who discontinued preventative therapy also used an acute treatment to manage migraine attacks after discontinuation (77.6%), generally in the year following discontinuation (68.4%). Patients on acute therapies were found to use triptans excessively (1.6%) and other non-migraine-specific acute medications for treatment (7.1%). Acute patients were also at risk of opioid dependence (12.0%) and commonly received opioids or barbiturates as first-line therapy (34.1%). Conclusion Newly diagnosed migraine patients are not being properly treated, as indicated by their excessive use of acute therapies and short time on preventive treatment before discontinuation of that treatment. Further study of the reasons why patients discontinue preventive therapy (adverse events, no response, etc.) and continue to excessively use acute treatments once their treatment regimen has been established is needed.

Details

Language :
English
ISSN :
21938253 and 21936536
Volume :
9
Issue :
1
Database :
Directory of Open Access Journals
Journal :
Neurology and Therapy
Publication Type :
Academic Journal
Accession number :
edsdoj.5c9ec14b5919412e92bdea5d39c74962
Document Type :
article
Full Text :
https://doi.org/10.1007/s40120-020-00179-3